Abstract
People who receive the ChAdOx1 nCoV-19 vaccine, particularly perimenopausal women who are on birth control or postmenopausal women who take estrogen supplements, may experience thrombosis and thrombocytopenia. Estrogen and the ChAdOx1 nCoV-19 vaccine both have the potential to cause thrombus in different ways. Some postmenopausal women who are also taking estrogens may develop thrombosis and thrombocytopenia after receiving the ChAdOx1 nCoV-19 vaccine. Therefore, women are encouraged to stop taking drugs containing estrogen before receiving this vaccine. Furthermore, consuming fish oil can help reduce the risk of developing blood clots among women who are in the luteal phase and, thus, have high estrogen levels. In addition, ChAdOx1 nCoV-19's side effects in young women could be mitigated by administering it during the follicular phase.
Highlights
Thrombose and Thrombocytopenia Induced by VaccinationThe ChAdOx1 nCoV-19 ( referred to as OxfordAstraZeneca) vaccine is classified as a recombinant chimpanzee adenoviral vector, and various countries have used it to treat cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, more commonly known as COVID19) [1, 2]
The ChAdOx1 nCoV-19 vaccine is classified as a recombinant chimpanzee adenoviral vector, and various countries have used it to treat cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, more commonly known as COVID19) [1, 2]
This condition is known as vaccine-induced immune thrombotic thrombocytopenia (VITT) [1]
Summary
The ChAdOx1 nCoV-19 ( referred to as OxfordAstraZeneca) vaccine is classified as a recombinant chimpanzee adenoviral vector, and various countries have used it to treat cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, more commonly known as COVID19) [1, 2]. Identical results were observed in a few people who received the Janssen COVID-19 vaccine (Ad26.COV2.S), which, like the Oxford-AstraZeneca vaccination, is based on an adenoviral vector This condition is known as vaccine-induced immune thrombotic thrombocytopenia (VITT) [1]. Further studies are needed to confirm whether pathologic platelet-activating anti-PF4 antibodies, unrelated to heparin therapy, and are linked to vaccination against SARS-CoV-2 [3] These patients have antibodies that bind to PF4-polyanion complexes at high levels [4, 5]. In one study conducted in Germany and Austria, 11 individuals experienced thrombosis or thrombocytopenia after receiving the Oxford-AstraZeneca vaccine Nine of these 11 patients were women, and they had a median age of 36 years [1]. Most of the patients in these studies were women under the age of 50, some of whom were taking oral contraceptives or undergoing estrogen replacement therapy [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
